戻る Agenda
[V8-S6] For Providing the Most Appropriate Medicine - The Current State of Use and Development of Companion Diagnostics (Mainly on Next Generation Sequencers)
Session Chair(s)
Kazuto Nishio, MD
Professor , Kindai University Faculty of Medicine, Japan
The existence of companion diagnostics is important for delivering medicine suitable for each patient. Genomic analysis is performed using next generation sequencer in cancer genome medical treatment, and genomic mutation for each patient and cell is revealed. In this session, present current status of “Precision Medicine” using Next Generation Sequencer, Issues in using next-generation sequencers, and issues of companion diagnostic drug development from the standpoint of each industry, government and academia. And also discuss the solution on panel-discussion.
Speaker(s)
Reiko Yanagihara, PHD
Deputy Review Director, Office of In Vitro Diagnostics, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Regulatory Perspectives on NGS-based CDx
Takashi Kohno, PHD
Division of Genome Biology, National Cancer Center Research Institute, Japan
NGS-Based Clinical Sequencing System for Precision Cancer Medicine in Japan
Miwa Nishida
Regulatory affairs, Roche Diagnostics K.K., Japan
Issue on the Development of CoDxs from Diagnostics Company’s Points of View
Michio Tanaka
Executive Officer, Division Vice president, Science & Data Technology Division, AstraZeneca K.K., Japan
Development of NGS- based CDx from a Pharmaceutical Company’s Viewpoint